Monitoring tumor changes in metastatic lobular breast cancer using blood tests
Official title: LBC-Monitor: Liquid Biopsy Guided Tailoring of Therapy in Metastatic Lobular Breast Cancer (mILC): A Pilot Study of Longitudinal Tumor Burden Quantification Using Circulating Tumor DNA
Run by University of Pittsburgh · NCT06666439 · Data updated 2026-11-12
This study is testing if tracking changes in tumor DNA from blood tests can help doctors better understand how well treatment is working for patients with advanced lobular breast cancer.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | Women only |
| Enrollment | 20 (estimated) |
| Sponsor | University of Pittsburgh Academic / other |
| Locations | 1 site (Pittsburgh, Pennsylvania) |
| Status | Recruiting |
| Started | December 12, 2024 |
| Main results expected | October 31, 2029 |
| Study ends | October 31, 2029 |
| Registry record updated | January 20, 2026 |
| Trial ID | NCT06666439 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults with histologically confirmed ER+ HER2-negative invasive lobular breast cancer who have evidence of metastatic disease and have not yet received therapy in the metastatic setting.
✕Probably not a fit
Patients with early-stage breast cancer (Stage I-III) or those who have already received therapy for metastatic disease may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to track early changes in circulating tumor DNA (ctDNA) in patients with metastatic invasive lobular carcinoma (mILC) to improve treatment strategies. By analyzing ctDNA, researchers hope to provide a more accurate assessment of treatment response compared to traditional imaging methods. The study focuses on patients who are starting first-line endocrine therapy, with the goal of identifying optimal early timepoints for monitoring molecular response. This approach could lead to more personalized treatment plans based on the dynamics of ctDNA changes.
Why it matters
Potential benefit: If successful, this study could enable more tailored and effective treatment strategies for patients with metastatic lobular breast cancer.
How similar studies have gone: While the use of ctDNA for monitoring treatment response is gaining traction, this specific approach in metastatic lobular breast cancer is relatively novel and has not been extensively tested in prior studies.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Signed informed consent 2. Patients must have histologically or cytologically confirmed invasive lobular breast cancer that is ER+ (\> 1% staining) and HER2-negative as per ASCO/CAP guidelines with radiographical or clinical evidence of metastatic disease 1. Lobular histology as assessed on either tissue collected from a metastatic lesion or from the patient's primary breast tumor (in case of recurrent metastatic disease) 2. Patients with mixed ductal/lobular (NST/ILC) tumors are eligible to participate (with the ultimate goal to evaluate 20 patients with pure ILC) 3. Patients must have tumor tissue available for whole exome sequencing for Signatera assay design 3. Prior therapies: 1. Patients must not have received any therapy in the metastatic setting 2. Patients could have received adjuvant therapy as indicated for their primary breast cancer 4. Age ≥ 18 years 5. Patients may be pre- or post-menopausal. Exclusion Criteria: 1. Stage I-III breast cancer 2. Lack of lobular histology on tumor tissue biopsy 3. Other active cancer (previously treated cancer with no current evidence of disease is allowed) 4. ctDNA assay development is unattainable due to insufficient tumor tissue or sequencing failure
Where it's running
-
Magee Women's Hospital of UPMC
Pittsburgh, Pennsylvania, United States Recruiting
Study contacts
- Principal investigator: Julia Foldi, MD, PhD — University of Pittsburgh
- Study coordinator: Lucia Borasso, BA
- Email: borrlm@upmc.edu
- Phone: 4126413304
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Imaging Mitochondrial Complex-I and Brain Metabolism in Alcohol Use Disorder
This study tests whether PET imaging with [18F]BCPP-EF and [18F]FDG can reveal differences in brain energy use between adults with alcohol use disorder and healthy controls, and whether these measures relate to relapse risk.
-
Imaging Brain Mitochondrial Complex-I in Cocaine Use Disorder
This study uses a PET scan with [F-18]BCPP-EF to see how mitochondrial Complex-I activity in the brain differs between people with cocaine use disorder and healthy controls.
-
Managing nighttime voiding in older women with sleep strategies
This study tests whether brief behavioral sleep therapy and mindfulness, alone or together, reduce how often older women wake at night to urinate and how much urine they produce at night.
-
Personalized pain relief for knee OA using central nervous system-based duloxetine
This study tests whether duloxetine can improve walking and daily activity in people with knee osteoarthritis by comparing it to a placebo.
-
Which antibiotic works best for kids with sinus infections?
This study tests whether amoxicillin, amoxicillin-clavulanate, or a placebo help children with acute sinusitis feel better faster.
-
Comparing Antibiotics and Placebo for Ear Infections in Toddlers
This trial tests whether amoxicillin, amoxicillin-clavulanate, or a placebo help reduce symptoms in children with acute otitis media.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.